Abarceo Pharma AB
559139-7160ActiveDeveloping novel small molecule therapeutics targeting VDAC1 for diabetes.
Biotechnology Companyabarceo.com
Yleiskatsaus
- 5–9
- Työntekijät
- 2.5–5milj SEK
- Liikevaihto
- 2017
- Perustettu
Avainpäättäjät
Mozhgan Dorkhan
Consulting CMO
Adam Bruce
CEO
Claes Post
Board Member
Claes Wollheim
CSO & Scientific Founder
+11 lisää yhteystietoja Funnelfeedrissä
Kuvaus
Abarceo Pharma is a pre-clinical stage biotechnology company founded in 2017 as a spin-out from the Lund University Diabetes Center. It was established by world-renowned scientists specializing in diabetes research and beta-cell biology. The company has identified Voltage-Dependent Anion Channel 1 (...